← Leaderboards
Mark K Slifka
Oregon Health And Science University
$36,595,057
Attributed
$46,524,606
Total exposure
38
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,524,606 · 38
By mechanism
R01$20,093,034 · 5
R44$9,212,812 · 2
U01$7,061,994 · 1
U44$5,372,018 · 2
P51$1,646,714 · 21
P01$925,491 · 1
Top collaborators
- Ian James Amanna19 shared
- Paul Kievit3 shared
- Charles T Roberts3 shared
- Daniel N Streblow3 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Daniel N Streblow$31,877,942
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesVirusInfectionResourcesResearch PersonnelHydrogen PeroxideTechnologyImmunogenicVaccinationImmunogenicityInfantVaccine CandidateElderlyProtective EfficacyVulnerable PopulationsUnited States National Institutes Of HealthGrantAdultProductionBaseInactivated VaccinesMacaca MulattaPhase I Clinical TrialsDose
Grant awards (78)
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$997,077
R01 · FY2025 · DK
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$980,963
U44 · FY2025 · AI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$986,133
U44 · FY2024 · AI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$951,400
R01 · FY2024 · DK
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$994,162
R01 · FY2023 · DK
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$825,048
U44 · FY2023 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$997,662
U44 · FY2022 · AI
Development of an improved intranasal vaccine against influenza$275,107
R41 · FY2022 · AI
An Advanced Vaccine Candidate To Prevent Zika Virus Infection$1,043,638
R01 · FY2021 · AI · contact PI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$999,652
U44 · FY2021 · AI
An Advanced Vaccine Candidate To Prevent Zika Virus Infection$1,093,491
R01 · FY2020 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$997,494
R44 · FY2020 · AI
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine$290,420
U44 · FY2020 · AI
An Advanced Vaccine Candidate To Prevent Zika Virus Infection$2,022,865
R01 · FY2019 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$996,895
R44 · FY2019 · AI
Development of an H2O2-inactivated chikungunya virus vaccine$989,109
R44 · FY2019 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine$292,140
U44 · FY2019 · AI
An Advanced Vaccine Candidate To Prevent Zika Virus Infection$1,341,359
R01 · FY2018 · AI · contact PI
Development of a Yellow Fever Vaccine for a Vulnerable Population$1,248,114
R44 · FY2018 · AI
Development of an H2O2-inactivated chikungunya virus vaccine$994,841
R44 · FY2018 · AI
An Advanced Vaccine Candidate To Prevent Zika Virus Infection$1,394,457
R01 · FY2017 · AI · contact PI
Development of an H2O2-inactivated chikungunya virus vaccine$999,652
R44 · FY2017 · AI
Development of an H2O2-Inactivated Dengue Virus Vaccine$1,395,722
R01 · FY2016 · AI · contact PI
Development of an H2O2-Inactivated Dengue Virus Vaccine$1,513,340
R01 · FY2015 · AI · contact PI
Development of an H2O2-Inactivated Dengue Virus Vaccine$1,488,158
R01 · FY2014 · AI · contact PI
Development of an H2O2-Inactivated Dengue Virus Vaccine$1,589,072
R01 · FY2013 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$994,154
R44 · FY2013 · AI
Development of an H2O2-Inactivated Dengue Virus Vaccine$1,327,554
R01 · FY2012 · AI · contact PI
Development of a Safe and Effective Vaccine Against West Nile Virus$1,097,443
U01 · FY2012 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$992,669
R44 · FY2012 · AI
Development of a Safe and Effective Vaccine Against West Nile Virus$3,039,791
U01 · FY2011 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Population$999,884
R44 · FY2011 · AI
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS$109,117
P51 · FY2011 · RR · contact PI
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED$58,239
P51 · FY2011 · RR · contact PI
Development of a Safe and Effective Vaccine Against West Nile Virus$2,128,280
U01 · FY2010 · AI · contact PI
Development of a new yellow fever vaccine for vulnerable populations$260,854
U54 · FY2010 · AI · contact PI
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS$95,066
P51 · FY2010 · RR · contact PI
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED$95,066
P51 · FY2010 · RR · contact PI
CYTOKINE-MEDIATED T CELL ACTIVATION$76,080
P51 · FY2010 · RR · contact PI
VACCINE-INDUCED CD8+ T CELL MEMORY$76,080
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS$47,603
P51 · FY2010 · RR · contact PI
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$47,603
P51 · FY2010 · RR · contact PI
Development of a Safe and Effective Vaccine Against West Nile Virus$796,480
U01 · FY2009 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,261
R43 · FY2009 · AI
Development of a new yellow fever vaccine for vulnerable populations$266,275
U54 · FY2009 · AI · contact PI
VACCINE-INDUCED CD8+ T CELL MEMORY$80,343
P51 · FY2009 · RR · contact PI
CYTOKINE-MEDIATED T CELL ACTIVATION$80,343
P51 · FY2009 · RR · contact PI
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$80,343
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS$60,393
P51 · FY2009 · RR · contact PI
Cytokine-mediated T cell activation$316,025
R01 · FY2008 · AI · contact PI
Vaccine-induced CD8+ T cell memory$308,000
R56 · FY2008 · AI · contact PI
Development of a Yellow Fever Vaccine for Vulnerable Populations$292,941
R43 · FY2008 · AI
B-CELL IMMUNITY IN PRIMATE SENESCENCE$271,505
P01 · FY2008 · AG · contact PI
RAPID DIAGNOSIS OF MONKEYPOX AND SMALLPOX INFECTIONS$55,512
P51 · FY2008 · RR · contact PI
CYTOKINE-MEDIATED T CELL ACTIVATION$55,512
P51 · FY2008 · RR · contact PI
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$55,512
P51 · FY2008 · RR · contact PI
Cytokine-mediated T cell activation$322,145
R01 · FY2007 · AI · contact PI
B-CELL IMMUNITY IN PRIMATE SENESCENCE$269,590
P01 · FY2007 · AG · contact PI
T cell activation and functional avidity$248,623
R01 · FY2007 · AI · contact PI
RAPID DIAGNOSIS OF MONKEYPOX AND SMALLPOX INFECTIONS$113,873
P51 · FY2007 · RR · contact PI
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$75,850
P51 · FY2007 · RR · contact PI
CYTOKINE-MEDIATED T CELL ACTIVATION$75,850
P51 · FY2007 · RR · contact PI
Cytokine-mediated T cell activation$331,767
R01 · FY2006 · AI · contact PI
T cell activation and functional avidity$256,049
R01 · FY2006 · AI · contact PI
B-CELL IMMUNITY IN PRIMATE SENESCENCE$180,542
P01 · FY2006 · AG · contact PI
CYTOKINE-MEDIATED T CELL ACTIVATION$76,828
P51 · FY2006 · RR · contact PI
Rapid Diagnosis of Monkeypox and Smallpox Infections$499,382
R41 · FY2005 · AI
Cytokine-mediated T cell activation$339,750
R01 · FY2005 · AI
T cell activation and functional avidity$262,210
R01 · FY2005 · AI
B-CELL IMMUNITY IN PRIMATE SENESCENCE$175,283
P01 · FY2005 · AG
CYTOKINE-MEDIATED T CELL ACTIVATION$74,664
P51 · FY2005 · RR
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$74,664
P51 · FY2005 · RR
Cytokine-mediated T cell activation$339,750
R01 · FY2004 · AI
T cell activation and functional avidity$262,210
R01 · FY2004 · AI
T CELL ACTIVATION AND FUNCTIONAL AVIDITY$82,173
P51 · FY2004 · RR
B-CELL IMMUNITY IN PRIMATE SENESCENCE$28,571
P01 · FY2004 · AG
Duration of smallpox immunity$17,723
M01 · FY2004 · RR
T cell activation and functional avidity$262,210
R01 · FY2003 · AI